WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory
AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
FDA grants Fast Track designation for Farxiga in heart failure 17 September 2019
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer 04 September 2019
FDA grants Fast Track designation for Farxiga in chronic kidney disease 27 August 2019
AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi 23 August 2019
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure 20 August 2019
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer 14 August 2019
Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease 20 June 2019
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever 22 May 2019
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer 08 May 2019
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery 30 April 2019
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
  • Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
  • Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare

Research & Development

  • COVAX announces new agreement, plans for first deliveries
  • Obesity, impaired metabolic health and COVID-19
  • COVID-19 has multiple faces
  • Metformin use reduces risk of death for patients with COVID-19 and diabetes
  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. AstraZeneca
  4. Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.